#Sustainability #South Korea #Dow Jones #Samsung Biologics #Incheon

Samsung Biologics: A Leader in Sustainability

Samsung Biologics, a prominent global contract development and manufacturing organization (CDMO), has once again made its mark in the Dow Jones Sustainability World Index (DJSI). This year marks the fourth consecutive time the company has been acknowledged for its exceptional dedication toward sustainability, aligning its practices with environmental, social, and governance (ESG) standards.

Located in Incheon, South Korea, Samsung Biologics has committed to implementing sustainable business practices throughout its operations, particularly focusing on ambitious environmental initiatives aimed at achieving net-zero emissions. John Rim, the President and CEO of Samsung Biologics, expressed pride in the company’s achievement, noting that it reflects their continuous drive towards sustainability not just for themselves but for the entire biopharma value chain. He stated, "This achievement demonstrates our commitment to driving sustainability across our operations and the broader biopharma value chain."

The company’s sustainability efforts have been recognized as entering a new phase through its involvement with the Sustainable Markets Initiative (SMI). As a leader in the Supply Chains Working Group of the SMI Health Systems Task Force, Samsung Biologics actively collaborates with global suppliers, working towards decarbonizing supply chains and fostering resilience against environmental challenges.

In addition to its commitment to carbon reduction, Samsung Biologics is transitioning to renewable energy sources via agreements for power purchase, received EcoVadis’ top-tier platinum sustainability rating, and has completed measurements of the Product Carbon Footprint to assist clients in reaching their own net-zero goals. The cumulative efforts underscore a holistic vision adopted by the organization, which integrates sustainability into every level of production and supply chain management.

The Road to Net-Zero

The pathway to net-zero emissions has become central to the mission of Samsung Biologics. Focused on reducing their carbon footprint, the company has developed various strategic plans to ensure that each aspect of their operations contributes to their net-zero ambitions. This includes investments in innovative technologies and renewable energy solutions aimed at minimizing environmental impact during the manufacturing processes.

Furthermore, Samsung Biologics has undertaken significant enhancements to expand its production capabilities, preparing for a future with increasing biomanufacturing demands. Recently, the company inaugurated Bio Campus II, which includes the construction of Plant 5 destined to become operational in April 2025, thus adding substantial biomanufacturing capacity. As part of an ongoing commitment to innovation, the company is investing in an antibody-drug conjugate (ADC) facility and enhancing mRNA-technologies to adapt to market dynamics.

Commitment to Global Health

Beyond its internal measures, Samsung Biologics is dedicated to contributing positively to the broader community and market by supporting its clients in achieving their ESG goals. As a reliable partner, the firm emphasizes on-time and full delivery of manufactured products, leveraging operational excellence and proven expertise. By facilitating a commitment to sustainability in their manufacturing solutions, they are playing a vital role in the evolution of the biopharmaceutical industry.

Ultimately, Samsung Biologics stands as a trailblazer in the sphere of sustainability and corporate responsibility, demonstrating that business growth can coincide with progressive environmental stewardship. Its ongoing success in the Dow Jones Sustainability World Index serves as both a recognition of its past efforts and a challenge for the future, keeping the company focused on its mission to create a healthier world for generations to come.